36 Respiratory depression, respiratory distress syndrome and apnoea - Milton Keynes Formulary

• Home
• Chapters
  • 1. Gastro-Intestinal System
  • 2. Cardiovascular system
  • 3. Respiratory System
  • 4. Nervous System
  • 5. Infections
  • 6. Endocrine System
  • 7. Obstetrics, Gynaecology and Urinary-tract Disorders
  • 8. Immune System and Malignant Disease
  • 9. Nutrition and Blood
  • 10. Musculoskeletal and Joint Diseases
  • 11. Eye
  • 12. Ear, Nose and Oropharynx
  • 13. Skin
  • 14. Immunological Products and Vaccines
  • 15. Anaesthesia
  • 16 Wound Management
  • 17. Miscellaneous Preparations
• Drugs
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
• MK Prescribing Advisory Group (MKPAG)
  • Application Forms
  • MKPAG Ratified Minutes
  • MKPAG Meeting Dates
  • Terms of Reference (ToR)
  • M&TC Minutes
• NICE Adherence Checklist
• GP Prescribing Group
  • Terms of reference
  • Minutes
  • Archived Minutes
• Shared Care Guidelines
• Local & National General Prescribing Information
  • 1. Financial and clinical responsibility for prescribing non-formulary drugs
  • 2. Repeat Prescribing Code of Practice
  • 3. When not to prescribe generically
  • 4. MK CCG Commissioning Policies
  • 5. Borderline Substances (ACBS)
  • 6. Selective List Scheme (SLS)
  • 7. Overseas visitors
  • 8. Travelling abroad
  • 9. Liquid Specials
  • 10. SPS Drug Monitoring Document Oct 2017
  • 11. Medication Information in Practices-November 2017
  • 12. Drugs That Prolong QT Interval
  • 13 Consultation Letter to Schools Nurseries-June 2017
  • 14 Letter to parents re changes in prescribing
  • 15. Self-Care Medicine List
• Biosimilar Position Statement
• Unlicensed Medicines
• Copyright Notice
• Patient Information Leaflets (New)
• About the Formulary Local Decisions
  • About the Joint Formulary
  • Format of the Formulary and Traffic Light Classification
• Newsletters
• Useful Links
• Contact Us

3.6 Respiratory depression, respiratory distress syndrome and apnoea

Traffic light status (TLS) explained:

• Red: Hospital or specialist prescribing only

Respiratory stimulants

Doxapram

• Injection 20mg/mL (100mg in 5mL amp)
• Infusion 2mg/mL in 5% glucose (1g in 500mL)

Mannitol Inhalation Capsules (Osmohale^®)

• Inhalation capsules 0mg, 5mg, 10mg, 20mg, 40mg

Note: 

• This medicinal product is for diagnostic use only. For identifying bronchial hyperresponsiveness in subjects with a baseline FEV1 of 70% or more of the predicted value.

Pulmonary surfactants

Beractant (Survanta^®)

• Suspension, beractant (bovine lung extract) providing phospholipid 25mg/mL, with lipids and proteins, 8-mL vial = 200mg 

Poractant alfa (Curosurf^®)

• Suspension, poractant alfa (porcine lung phospholipid fraction) 80mg/mL, 1.5-mL vial = 120mg; 3-mL vial = 240mg

Neonatal Apnoea 

Xanthines 

Caffeine citrate   

• Oral solution 10mg/mL
• Solution for Injection 10mg/mL
• Solution for infusion 20mg/mL (Peyona®)

Return to Chapter: 3. Respiratory System

Last updated by: Dupe Fagbenro on 12-12-2018 16:51